Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company's CEO, Catherine Owen Adams, will lead the presentation scheduled for 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Investors and interested parties can access a live webcast of the event through the Acadia website, where an archived version will also be available for approximately one month post-event.

Acadia is dedicated to advancing scientific research to provide innovative solutions for underserved communities impacted by neurological and rare diseases. The company's commercial portfolio boasts the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. Acadia's ongoing commitment to expanding its therapeutic offerings is reflected in a promising pipeline that features mid- to late-stage programs targeting Alzheimer’s disease psychosis and Lewy body dementia psychosis. Additionally, the company is exploring earlier-stage programs aimed at fulfilling other unmet medical needs in these patient populations.

By leveraging scientific advancements, Acadia aims to make a meaningful impact in the lives of patients suffering from complex neurological disorders. The company’s focus on innovation underscores its mission to be a catalyst for change in the healthcare landscape.

For further inquiries, Acadia has provided contact details for their investor relations and media teams. Stakeholders are encouraged to visit Acadia’s website for more information and updates on its initiatives and presentation. With a strong commitment to addressing critical health challenges, Acadia Pharmaceuticals continues to position itself as a leader in the field of neurology.

Acadia Pharmaceuticals (Nasdaq: ACAD) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, which may serve as a significant catalyst for its stock performance. With the company's commitment to addressing unmet medical needs in the neurology space, investors should closely monitor both the presentation and the market's reaction.

Acadia has established itself through innovative therapeutic offerings, notably its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. The upcoming presentation is a prime opportunity for the CEO, Catherine Owen Adams, to outline Acadia's strategic vision and the potential of its diverse pipeline, which includes therapies for Alzheimer’s disease psychosis and Lewy body dementia psychosis. Investors should pay particular attention to any new data revealed during the conference, as promising updates can lead to enhanced investor confidence and significant stock price movements.

Moreover, Acadia's focus on underserved markets positions it well to tap into a growing demand for specialized treatments. As the landscape of neurology evolves, the success of late-stage clinical trials, especially those addressing Alzheimer’s-related conditions, could create substantial company value and drive revenue growth.

While Acadia faces competition from other biopharmaceutical firms, its unique portfolio provides a competitive edge. Investors should consider the potential implications of the ongoing healthcare industry trends towards personalized medicine and innovative trial designs, which may benefit Acadia's approach.

In summary, stakeholders should stay informed about product developments and market trends leading up to the conference. A strategic buy-and-hold approach may be prudent, especially in a sector ripe for innovation. However, investors may also want to set risk management strategies in place, balancing potential rewards against possible volatility characteristic of biotech stocks.